Clinical observation of microwave ablation combined with chemotherapy and PD-1 inhibitor for non-small cell lung cancer
10.3969/j.issn.1673-9701.2025.21.011
- VernacularTitle:微波消融联合化疗+PD-1抑制剂治疗NSCLC的临床观察
- Author:
Na LI
1
;
Bingqing LUO
1
Author Information
1. 厦门医学院附属第二医院肿瘤内科,福建厦门 361021
- Publication Type:Journal Article
- Keywords:
Microwave ablation;
Non-small cell lung cancer;
PD-1 inhibitor;
Progression-free survival
- From:
China Modern Doctor
2025;63(21):47-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy and safety of microwave ablation(MWA)combined with chemotherapy and programmed death-1(PD-1)inhibitor in the treatment of non-small cell lung cancer(NSCLC).Methods The data of 73 patients with NSCLC who were received MWA combined with chemotherapy+PD-1 inhibitor or PD-1 inhibitor+chemotherapy in the Second Affiliated Hospital of Xiamen Medical College from May 2021 to May 2022 were retrospectively collected.The patients received chemotherapy plus PD-1 inhibitor with or without MWA were divided into combination group(n=40)and control group(n=33)according to different treatment regimens.Patients in control group were treated with PD-1 inhibitor combined with chemotherapy,while patients in combination group received additional MWA on the basis of PD-1 inhibitor combined with chemotherapy.Overall effective rate(OR),disease control rate(DCR),progression-free survival(PFS),and incidence of adverse events of two groups were compared and analysed.Results OR and DCR in combination group was 72.50％and 95.00％.with 54.54％ and 81.81％ respectively in control group,there was no statistically significant difference between two groups in terms of OR and DCR(P＞0.05).The median PFS in combination group was 12.4 months,significantly longer than 8.5 months in control group(P＜0.001).Forty patients who underwent MWA did not experience any severe adverse reactions.Among 73 patients who received chemotherapy combined with PD-1 inhibitor treatment,the adverse reactions were mainly grade 1 to grade 2,with two patients experienced grade 3 adverse reactions.Conclusion MWA combined with chemotherapy plus PD-1 inhibitor can prolong PFS of patients with NSCLC and has good safety.
